Literature DB >> 3102485

Characterization of recombinant human factor VIII.

D L Eaton, P E Hass, L Riddle, J Mather, M Wiebe, T Gregory, G A Vehar.   

Abstract

Recently, complete human factor VIII DNA clones have been obtained and subsequently expressed in baby hamster kidney cells (Wood, W. I., Capon, D. J., Simonsen, C. C., Eaton, D. L., Gitschier, J., Keyt, B., Seeburg, P. H., Smith, D. H., Hollingshead, P., Wion, K. L., Delwart, E., Tuddenham, E. G. D., Vehar, G. A., and Lawn, R. M. (1984) Nature 312, 330-337). The recombinant factor VIII (rVIII) protein secreted from these cells has now been purified allowing its structural analysis and comparison to plasma-derived factor VIII (pdVIII). Analysis of purified rVIII by sodium dodecyl sulfate-polyacrylamide gel electrophoresis shows that it consists of multiple polypeptides with relative mobilities (Mr) ranging from 80,000-210,000. The same pattern of polypeptides is also observed for pdVIII resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins associated with rVIII are recognized by pdVIII antibodies in a Western blot. When rVIII and pdVIII are subjected to isoelectric focusing they are resolved into a similar pattern of protein bands. Thrombin, factor Xa, and activated protein C, which modulate factor VIII activity by proteolysis, process rVIII in the same manner they do pdVIII. As is the case for pdVIII, thrombin activation of rVIII coagulant activity correlates with the generation of subunits with Mr of 73,000, 50,000 and 43,000. These subunits appear to form a metal-(perhaps Ca2+) linked complex. EDTA inactivates thrombin-activated rVIII and pdVIII, with the activity being regenerated after the addition of a molar excess of MnCl2. The results suggest that rVIII is structurally and functionally very similar to pdVIII.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102485

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Correlation of rFVIII inactivation with aggregation in solution.

Authors:  Wei Wang; Drew N Kelner
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

Review 2.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

3.  Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.

Authors:  N Bihoreau; P Paolantonacci; C Bardelle; M P Fontaine-Aupart; S Krishnan; J Yon; J L Romet-Lemonne
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

4.  Expression of human coagulation factor VIII in a human hybrid cell line, HKB11.

Authors:  Baisong Mei; Yaoqi Chen; Jianmin Chen; Clark Q Pan; John E Murphy
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

5.  Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry.

Authors:  J Spaargaren; P L Giesen; M P Janssen; J Voorberg; G M Willems; J A van Mourik
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

6.  Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.

Authors:  W M McCORMACK; M P Seiler; T K Bertin; K Ubhayakar; D J Palmer; P Ng; T C Nichols; B Lee
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

7.  Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.

Authors:  Sara Pérez-Luz; Javier Díaz-Nido
Journal:  J Biomed Biotechnol       Date:  2010-08-24

8.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

9.  Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.

Authors:  P A Foster; C A Fulcher; R A Houghten; S de Graaf Mahoney; T S Zimmerman
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

Review 10.  Gene therapy for haemophilia.

Authors:  Samuel L Murphy; Katherine A High
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.